PlumX Metrics
Embed PlumX Metrics

Clinical Impact of Additional Cilostazol Treatment on Restenosis Risk following Heparin-Bonded Stent Graft Implantation: Sub-Analysis from the Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study

Journal of Atherosclerosis and Thrombosis, ISSN: 1880-3873, Vol: 30, Issue: 10, Page: 1461-1470
2023
  • 1
    Citations
  • 0
    Usage
  • 8
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    1
  • Captures
    8
  • Mentions
    1
    • News Mentions
      1
      • 1

Most Recent News

Investigators at Shonan Kamakura General Hospital Discuss Findings in Restenosis [Clinical Impact of Additional Cilostazol Treatment On Restenosis Risk Following Heparin-bonded Stent Graft Implantation: Sub-analysis From the Viabahn Stent-graft ...]

2023 APR 03 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Research findings on Restenosis are discussed in a new

Article Description

Aim: The present study investigated the effects of additional cilostazol administration on the 12-month risk of restenosis after femoropopliteal heparin-bonded stent graft implantation. Methods: This study was a sub-analysis of the Viabahn stent graft placement for femoropopliteal disease reQUIring endovaScular tHerapy (VANQUISH) study, which was a prospective multicenter study investigating patients who received Viabahn stent graft (W.L. Gore & Associates, Flagstaff, AZ, USA) and dual-antiplatelet therapy with aspirin and a thienopyridine. The comparison of clinical outcomes between subgroups with and without cilostazol treatment were performed using the propensity score-matching method to minimize the intergroup differences in baseline characteristics. Results: Cilostazol-treated patients had a lower 12-month proportion of restenosis than cilostazol-free patients (8.2% vs 27.3%). The odds ratio of cilostazol for the 12-month restenosis was 0.27 [95% CI, 0.08 to 0.97] (p=0.045). Furthermore, the cumulative incidence rates of surgical reconstruction, target lesion revascularization and acute thrombotic occlusion (p values by the log-rank test) were 2.6% versus 1.8% (P=0.43), 5.3% versus 20.5% (P=0.067), and 0.0% versus 11.8% (P=0.0499), respectively. The rates of surgical reconstruction and target lesion revascularization (TLR) were not significantly different between both groups. Conclusions: Our study revealed the clinical impact of additional cilostazol treatment on the risk of restenosis and acute thrombotic occlusion following heparin-bonded stent graft implantation, while TLR and surgical reconstruction were not significantly different.

Bibliographic Details

Tobita, Kazuki; Takahara, Mitsuyoshi; Iida, Osamu; Soga, Yoshimitsu; Yamaoka, Terutoshi; Ichihashi, Shigeo; Saito, Shigeru

Japan Atherosclerosis Society

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know